Public disclosure ledger
Congress trades, connected to people and prices.
Filter the source ledger, open a member profile, inspect the ticker, and see how the market moved after the reported transaction date.
Matching disclosures
41
records in the current view
Linked members
13
politician profiles represented
Ticker coverage
1
unique stock symbols
Reported purchases
18
purchase-labeled transactions
Source records
Latest matching disclosures
| Date | Member | Ticker | Action | Disclosed range ▲ | Asset / owner | Since trade | Source |
|---|---|---|---|---|---|---|---|
| Aug. 11, 2025 senate | John Boozman Joint | ABBV | SALE (PARTIAL) | $1,001 - $15,000 | Abbvie IncJoint | ▲ +24.69% | Open ↗ |
| Aug. 22, 2025 senate | John Boozman Joint | ABBV | SALE (PARTIAL) | $1,001 - $15,000 | Abbvie IncJoint | ▲ +24.69% | Open ↗ |
| Apr. 3, 2024 senate | Tommy Tuberville Joint | ABBV | PURCHASE | $1,001 - $15,000 | AbbVie Inc. Common StockJoint | ▲ +24.69% | Open ↗ |
| Jan. 19, 2024 senate | Tommy Tuberville Joint | ABBV | SALE (FULL) | $1,001 - $15,000 | AbbVie Inc. Common StockJoint | ▲ +24.69% | Open ↗ |
| Nov. 20, 2023 senate | Tommy Tuberville Joint | ABBV | SALE (FULL) | $1,001 - $15,000 | Abbvie IncJoint | ▲ +24.69% | Open ↗ |
| Oct. 17, 2023 senate | Tommy Tuberville Joint | ABBV | PURCHASE | $1,001 - $15,000 | AbbVie Inc. Common StockJoint | ▲ +24.69% | Open ↗ |
| Apr. 3, 2023 senate | Tommy Tuberville Joint | ABBV | SALE (PARTIAL) | $1,001 - $15,000 | AbbVie Inc. Common StockJoint | ▲ +24.69% | Open ↗ |
| Apr. 3, 2023 senate | Tommy Tuberville Joint | ABBV | SALE (PARTIAL) | $1,001 - $15,000 | AbbVie Inc. Common StockJoint | ▲ +24.69% | Open ↗ |
| Mar. 30, 2022 senate | Tommy Tuberville Joint | ABBV | PURCHASE | $1,001 - $15,000 | AbbVie Inc. Common StockJoint | ▲ +24.69% | Open ↗ |
| Jan. 29, 2026 house | Ro Khanna Spouse | ABBV | SALE | $15,001 - $50,000 | AbbVie IncSpouse | ▲ +24.69% | Open ↗ |
| May. 1, 2026 house | Ro Khanna | ABBV | PURCHASE | $15,001 - $50,000 | AbbVie Inc | ▲ +24.69% | Open ↗ |
Price changes are research context, not copy-trading returns.